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Increasing numbers of countries are using indi-
cators to evaluate the quality of clinical care, 
with some linking payment to achievement.1 
For performance frameworks to remain effective 
the indicators need to be regularly reviewed. The 
frameworks cannot cover all clinical areas, and 
achievement on chosen indicators will even-
tually reach a ceiling beyond which further 
improvement is not feasible.2 3 However, there 
has been little work on how to select indictors for 
replacement. The Department of Health decided 
in 2008 that it would regularly replace indicators 
in the national primary care pay for performance 
scheme, the Quality and Outcomes Framework,4 
making a rigorous approach to removal a prior-
ity. We draw on our previous work on pay for 
performance5 6 and our current work advising 
the National Institute for Health and Clinical 
Excellence (NICE) on the Quality and Outcomes 
Framework to suggest what should be consid-
ered when planning to remove indicators from 
a clinical performance framework.
First UK decisions 
The Quality and Outcomes Framework cur-
rently includes 134 indicators for which gen-
eral practices can earn up to a total of 1000 
points. Negotiations between the Department 
of Health and the BMA’s General Practitioners 
 Committee last autumn led to an agreement to 
remove eight clinical indicators worth 28 points 
in April 2011 (table 1). The eight indicators are 
all process measures and reward actions such as 
taking blood pressure or taking blood to measure 
 cholesterol, glucose, or creatinine concentra-
tions for people with relevant chronic diseases. 
The framework rewards the action itself rather 
than a clinically informed response to results or 
intermediate outcomes such as better control of 
blood pressure or cholesterol levels. It is there-
fore not surprising that achievement of these 
process indicators is high (median >95% and 
interquartile range <4.5%) with little change in 
rates or variation across practices since 2005-6, 
the second year of the Quality and Outcomes 
Framework. 
In many schemes, including the Quality and 
Outcomes Framework, providers can “except” 
certain patients from inclusion in the denomi-
nator figures for an indicator on grounds such as 
extreme frailty or contraindications to a specified 
drug. Exception reporting rates are also low for 
these eight indicators (median <5% and inter-
quartile range <3%).
How to identify when a performance 
indicator has run its course 
In April 2011 eight clinical indicators will be removed from the UK Quality and Outcomes  
Framework. David Reeves and colleagues explain why they were chosen and suggest  
a rationale for future decisions 
National achievement and exception rates for indicators that are to be removed from the Quality and Outcomes Framework in 20117
Indicator (measurement of ) Condition
Median (interquartile range) achievement (%) Median (interquartile range) rate of exceptions (%) Paired 
indicator*2005-6 2006-7 2007-8 2005-6 2006-7 2007-8
Blood pressure Coronary heart disease 98.2 (96.7-99.3) 98.5 (97.2-99.5) 98.4(97.1-99.4) 0.8 (0-1.8) 0.8  (0-1.7) 0.7 (0-1.6) Yes 
Haemoglobin A1c Diabetes 97.4 (95.1-98.8) 97.8 (95.9-99.0) 97.7 (96.0-98.9) 2.7 (1.4-4.4) 2.5 (1.3-4.2) 2.4 (1.2-3.9) Yes 
Blood pressure Diabetes 98.8 (97.6-99.7) 99.0 (98.0-100) 98.9 (97.9-99.6) 1.1 (0.3-2.2) 1.0 (0.3-2.1) 1.0 (0.3-2.1) Yes 
Serum creatinine Diabetes 96.7 (94.1-98.3) 97.4 (95.3-98.7) 97.4 (95.6-98.7) 1.9 (0.9-3.4) 1.7 (0.8-3.2) 1.6 (0.7-3.1) No
Total cholesterol Diabetes 96.4 (93.8-98.1) 96.9 (94.8-98.3) 96.8 (94.8-98.2) 2.2 (1.1-3.9) 2.1 (1.0-3.8) 2.0 (0.9-3.6) Yes 
Serum creatinine and thyroid 
stimulating hormone  
Mental health (lithium) 100 (100-100) 100 (100-100) 100 (100-100) 0 (0-0) 0 (0-0) 0 (0-0) No
Blood pressure Stroke 97.4 (95.1-100) 97.7 (95.8-100) 97.6 (95.8-99.5) 1.3 (0-3.3) 1.2 (0-2.9) 1.1 (0-2.7) Yes
Thyroid function Hypothyroidism 96.8 (94.5-98.7) 96.7 (94.5-98.5) 96.5 (94.3-98.3) 0 (0-0.9) 0 (0-0.9) 0 (0-0.8) No
*Paired indicators relate to control of the relevant measure—for example, the indicator that focuses on recording blood pressure in patients with coronary heart disease, is paired with another 
indicator that rewards on the basis of the proportion of patients whose last blood pressure reading was ≤150/90 mm Hg.
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 If we look at one of the eight indicators in more 
detail—the proportion of diabetic patients who 
have had their blood pressure measured in the 
previous 15 months—the reason for removal is 
clear. Performance has been extremely high and 
stable since 2005-6 both in terms of achievement 
(median around 99%) and exception reporting 
(around 1%), with low interpractice variation 
(table). Indeed, over 99% of practices scored 
maximum points (21% had 100% achievement), 
and the average remuneration for practices on 
this indicator was £374.40 (£3.1m nationally 
each year). These results strongly suggest that the 
ceiling has been reached in performance for this 
indicator and little can be gained from continuing 
to reward it. 
 However, the associated intermediate outcome 
indicator (the proportion of people with diabe-
tes with blood pressure ≤145/85 mm Hg in the 
previous 15 months) will 
remain in the 2011 frame-
work. Although there have 
been moderate gains in 
performance since 2005-
6, median achievement 
and exception rates in 
2007-8 were 80% and 
5.7% respectively. 7 It 
may not be possible to 
reach the same level of 
performance for interme-
diate outcome indicators 
as for process indicators; 
however, around 10% of practices have attained 
achievement rates of ≥90% and exception rates of 
<2%, showing that higher performance is possi-
ble. It would therefore be inappropriate to remove 
this indicator. 
 Criteria for removing indicators 
 Indicators that are candidates for removal from 
a framework should be identified largely on the 
basis of statistical criteria, with the final decision 
often determined by the context. Statistical crite-
ria consider measures of performance as well as 
the economics of incentives. Economic analysis 
considers the net benefit of incentives by quan-
tifying the costs of the indicator relative to the 
health benefits accrued. If the benefits outweigh 
the costs it is economically justifiable to continue 
to reward good performance. This approach is 
particularly suited to indicators that are associ-
ated with a direct therapeutic benefit but is less 
suited to process indicators such as measur-
ing blood pressure, where it may be difficult to 
attribute or quantify any resulting health benefit. 
We therefore suggest that economic analysis is 
not routinely used for process indicators. 
 The performance of an indicator should be 
assessed in at least five ways:  
 • Average rate of achievement  
 • Recent trend in achievement rate 
 • Extent and trend in variation of achievement 
rate 
 • Average rate and trend in exception 
reporting  
 • Extent and trend in variation of exception 
rate.  
 If the rates have skewed distributions, medians 
and interquartile ranges may be more appropriate 
measures than means and standard  deviations. 
 The average reported achievement rate—the 
percentage of eligible patients for whom the 
indicator target has been achieved—should be 
high. It is difficult to set 
one definition of high for 
all indicators because 
some, particularly inter-
mediate outcomes, such 
as achieving low choles-
terol levels, are unlikely 
to ever reach as high 
rates as, say,  process 
indicators. One solu-
tion is to use a different 
empirical definition of 
high for each indicator—
for example, by using the 
achievement rates of the top 10% during the first 
year of the indicator’s operation. 
 Examination of trends in performance can help 
identify indicators that have reached the limits of 
achievement. This is signalled either by consist-
ently high performance or by a period of growth 
followed by a plateauing of the curve. Indicators 
for which improvement shows no signs of flatten-
ing off are less likely to be candidates for replace-
ment. A variable pattern of improvement may 
signal a wider problem. A lack of change when 
there is clear room for improvement suggests a 
substantial mismatch between the magnitude of 
the incentive and the workload required. 
 Achievement rates will depend on a range of 
factors, only some of which will be under the 
control of providers. 8 When factors outside pro-
viders’ control have been allowed for, variation 
in achievement rates should be low. A wide varia-
tion in achievement suggests that many providers 
could substantially improve their performance. 
 Average rates of exceptions and variations 
in these rates should be low. It would be inap-
propriate to replace an indicator for which a 
large proportion of patients with the condition 
are excepted without first determining the rea-
son for the high level of exceptions, including 
the possibility that the indicator had poor face 
validity and was not seen as useful in clinical 
practice. Indeed, one of the next tasks of the 
external contractor team employed by NICE to 
help develop the framework is to look in detail 
at indicators with high exception reporting as 
well as high achievement. One such indicator is 
the percentage of patients with newly diagnosed 
angina who are referred for exercise testing or 
specialist assessment. What constitutes a low 
exception rate may vary by indicator, but a good 
indication that a practical limit has been reached 
is low variation in the rate between practices. 
 Even if an indicator satisfies the statistical cri-
teria for removal, contextual factors, which  con-
sider the wider framework in which the indicator 
is operating, may make removal inappropriate. 
Contextual factors include policy considerations 
such as maintaining an appropriate balance of 
indicators across disease domains; stakeholder 
perspectives such as concerns of health profes-
sionals about additional workload and reliance 
on incentives 9 ; and concerns of patients and user 
groups about perceived loss of prioritisation of 
their condition. Indeed, the public seems to per-
ceive inclusion in the framework to be important 
for good care. When the Department of Health 
invited ideas for inclusion in the framework in 
2007, for example, 153 were received in five 
weeks, 52% of which came from national dis-
ease societies or local patient groups. 
 Another consideration is circumstances 
affecting the validity of the indicator, such as 
changes in evidence. For example, the frame-
work currently contains an indicator for the 
percentage of patients taking lithium who have a 
record of plasma concentrations in the therapeu-
tic range within the past six months. However, 
a recent National Patient Safety Agency alert 
reported 567 dosage errors for lithium, five of 
which occurred in primary care. 10  The indica-
tor may need to be reviewed in the light of this 
and 2006 NICE guidance that lithium concen-
trations should “normally” be measured every 
three months. 11 
 Consequences of replacement 
 We have proposed selecting indicators for 
replacement on the basis of each indicator’s 
recent history of achievement and exception 
Ultimately, we need to know what will happen to 
performance if an indicator is replaced. Empirical 
evidence from the United Kingdom is limited
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reporting rates. Underlying this approach is an 
assumption that this provides a good guide to 
the future performance of that indicator. The 
approach, however, provides no actual esti-
mates of future performance, nor any measure 
of the degree of uncertainty in the forecast. This 
is something that we plan to explore in the near 
future.
Ultimately, we need to know what will hap-
pen to performance if an indicator is replaced. 
Empirical evidence from the United Kingdom is 
limited. There is some conflicting evidence from 
performance on two indicators removed for con-
textual reasons from the Quality and Outcomes 
Framework in 2006. In a sample of 150 prac-
tices in which performance was tracked, immu-
nisation of asthmatic patients against influenza 
showed a substantial reduction in achievement 
rates after it was removed from the framework, 
but there was no such reduction for check-
ing lithium concentrations in patients taking 
the drug. This process indicator, however, was 
paired with an intermediate outcome indicator 
(the percentage of patients taking lithium with a 
record of lithium levels in the therapeutic range 
within the past six months), which remained in 
the framework. 
Strategies to minimise the risk of harm from 
removal might include a gradual reduction of 
the payments for achieving indicators or, as in 
the above example, initially to remove half of a 
paired indicator, so that the removed process is 
still incorporated as part of a linked intermediate 
outcome indicator. 
Finally, removed indicators need to be moni-
tored within the framework. A new centrally 
managed tool for extracting the necessary data 
from practices’ clinical computing systems—the 
General Practice Extraction Service—is due to be 
operational in England by 2011.12 In the mean-
time, large scale general practice databases that 
allow interrogation of electronically captured 
patient consultation data, such as the General 
Practice Research Database, QRESEARCH, and 
the Health Improvement Network, could be used 
to identify general trends.
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The value of an 
intercalated BSc
Helen Jaques asks 
why more medical 
students in the United 
Kingdom don’t take the 
opportunity to study 
for an intercalated 
Bachelor of Science 
degree as part of 
their medical degree. There are numerous 
advantages—“a key benefit of doing an 
intercalated BSc is the edge it gives in the 
job market: having a BSc is worth between 
2 and 6 extra points in the UK foundation 
programme, which is the route through 
which medical students get their first junior 
doctor job after graduating,” she writes. 
“Undergraduates who do an intercalated 
BSc also do better in subsequent medical 
exams than those who don’t do the extra 
year.” And yet only 30% of students choose 
to do an intercalated BSc and that number 
seems to be declining.
Vidhya Alakeson writes about the task the 
US government now faces to put the health 
reform bill into practice. “It is time for the 
hard work of implementing the pages of 
provisions included in the health reform bill 
that was passed by Congress last month,” 
she says. “While the media coverage has 
rightly focused on the historic extension 
of health insurance to cover most of the 47 
million uninsured Americans, the legislation 
contains many other provisions that are 
worth a closer look, particularly in light of 
current priorities within the NHS.”
Tracey Koehlmoos was surprised on a recent 
visit to Jakarta to see a 25 foot poster of the 
Marlboro Man. Smoking is big problem in 
Indonesia. “We switched tables at more than 
one restaurant when someone lit up right 
next to us,” she says. “People smoke on the 
streets, at bus stops and in restaurants. I 
learned that some 64% of men in Indonesia 
smoke—that is approximately 57 million 
people.”
• Read these articles and other BMJ 
blogs at http://blogs.bmj.com/bmj
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